Matinas BioPharma Holdings Inc Share Price Other OTC
Equities
US5768101058
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
||
0.175 USD | 0.00% |
09/05 | Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 43.39M 3.61B |
---|---|---|---|---|---|
Net income 2024 * | -25M -2.08B | Net income 2025 * | -34M -2.83B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-1.57
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
Latest transcript on Matinas BioPharma Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 01/13/01 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 03/19/03 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 01/13/01 |
Natasha Giordano
BRD | Director/Board Member | 62 | 14/20/14 |
Eric Ende
CHM | Chairman | 55 | 03/17/03 |
1st Jan change | Capi. | |
---|---|---|
+8.89% | 114B | |
+11.47% | 104B | |
-12.59% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.07% | 17.89B | |
+7.77% | 14.28B | |
+35.97% | 12.55B |